MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
Synonyms: MK-0354
This is just here as a test because I lose it
Term information
database
cross reference
- CAS:851776-28-8
- BindingDB:50273099
- ChemSpider:9334721
- ChEMBL:CHEMBL456145
- Wikipedia:G_protein-coupled_receptor
hasDbXref
ChEMBL:CHEMBL456145
Wikipedia:G_protein-coupled_receptor
BindingDB:50273099
CAS:851776-28-8
ChemSpider:9334721